ArticleScientific reports2017
Immunization with alkyl hydroperoxide reductase subunit C reduces Fusobacterium nucleatum load in the intestinal tract.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Impact of alcohol on gut microbial metabolism and the gut-liver-brain axis.Alcohol (Fayetteville, N.Y.) · 2026Review
- Fusobacterium nucleatum: ecology, pathogenesis and clinical implications.Nature reviews. Microbiology · 2026Review
- Microbiome-Genome Crosstalk in Colorectal Cancer: Colibactin Signatures andInternational journal of molecular sciences · 2026Review
- Review
- Review
- Emerging strategies for combatingExploration (Beijing, China) · 2024Review
- Fn-Dps, a novel virulence factor of Fusobacterium nucleatum, disrupts erythrocytes and promotes metastasis in colorectal cancer.PLoS pathogens · 2023Article
- Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC.Infection and immunity · 2022Article
- Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism.Frontiers in cellular and infection microbiology · 2022Review
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Fusobacterium nucleatum and oral cancer: a critical review.BMC cancer · 2021Review
- Targeting ProgrammedCancers · 2019Review
- Fusobacterium nucleatum - symbiont, opportunist and oncobacterium.Nature reviews. Microbiology · 2019Review
- Molecular Mechanisms of AhpC in Resistance to Oxidative Stress inFrontiers in microbiology · 2019Article
- Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer.Journal of gastroenterology · 2019Review
- Association betweenJournal of Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusobacterium nucleatum (Fn) is an important tumour-associated bacterium in colorectal cancer (CRC). The antioxidant protein alkyl hydroperoxide reductase subunit C (AhpC) can induce strong antibacterial immune response during various pathogen infections. Our study aimed to evaluate the efficacy of Fn-AhpC as a candidate vaccine. In this work, by western blot analysis, we showed that Fn-AhpC recombinant protein could be recognized specifically by antibodies present in the sera of CRC patients; using the mouse Fn-infection model, we observed that systemic prophylactic immunization with AhpC/alum conferred significant protection against infection in 77.3% of mice. In addition, we measured the anti-AhpC antibody level in the sera of CRC patients and found that there was no obvious increase of anti-AhpC antibodies in the early-stage CRC group. Furthermore, we treated Fn with the sera from both immunized mice and CRC patients and found that sera with high anti-AhpC antibodies titre could inhibit Fn growth. In conclusion, our findings support the use of AhpC as a potential vaccine candidate against inhabitation or infection of Fn in the intestinal tract, which could provide a practical strategy for the prevention of CRC associated with Fn infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.